(Lung Cancer) Is Next-Generation ALK Inhibitor Ensartinib Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- January 1, 2020
- Reading time: 2 minutes
On October 15, 2019, Yunpeng Yang published results in The Lancet Respiratory Medicine from a Phase II clinical trial evaluating ensartinib monotherapy in ALK-positive non-small cell lung cancer (NSCLC) patients with crizotinib resistance, assessing its efficacy and safety.
This Phase II trial was a single-arm, open-label study conducted in ALK-positive NSCLC patients with crizotinib resistance (N=160). Patients received ensartinib 225 mg once daily. The primary endpoint was objective response rate (ORR); secondary endpoints included safety. Of the 160 patients, 62% (N=97) had brain metastases at baseline.
Results:
Among evaluable patients, the primary endpoint ORR was 52%. Among evaluable patients with brain metastases, the ORR was 70%.
Safety:
At least one adverse event was reported in 91% of patients (145/160). The most common adverse events were skin disorders (56%, N=89), ALT elevation (46%, N=74), and AST elevation (41%, N=65).
Based on the Phase II clinical trial results, Yunpeng Yang concluded that ensartinib monotherapy demonstrated favorable antitumor activity in crizotinib-resistant, ALK-positive NSCLC patients, including those with brain metastases. Further clinical trials are warranted to confirm its utility.
Source: Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial (Lancet Respir Med. 2019 Oct 15. pii: S2213-2600(19)30252-8. doi: 10.1016/S2213-2600(19)30252-8.)
#LungCancer #Ensartinib
- Clinical trial drugs
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4